Details

Autor(en) / Beteiligte

• Dai, Ming Shen
• Feng, Yin Hsun
• Chen, Shang Wen
• Masuda, Norikazu
• Yau, Thomas
• Chen, Shou Tung
• Lu, Yen Shen
• Yap, Yoon Sim
• Ang, Peter C. S.
• Chu, Sung Chao
• Kwong, Ava
• Lee, Keun Seok
• Ow, Samuel
• Kim, Sung Bae
• Lin, Johnson
• Chung, Hyun Cheol
• Ngan, Roger
• Kok, Victor C.
• Rau, Kun Ming
• Sangai, Takafumi
• Ng, Ting Ying
• Tseng, Ling Ming
• Bryce, Richard
• Bebchuk, Judith
• Chen, Mei Chieh
• Hou, Ming Feng

Titel

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

Ist Teil von

• Breast cancer research and treatment, 2021-10, Vol.189 (3), p.665-676

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, has demonstrated systemic efficacy and intracranial activity in various stages of HER2+breast cancer. NALA was a phase III randomized trial that assessed the efficacy and safety of neratinib+capecitabine (N+C) against lapatinib+capecitabine (L+C) in HER2+ metastatic breast cancer (mBC) patients who had received ≥ 2 HER2-directed regimens. Descriptive analysis results of the Asian subgroup in the NALA study are reported herein. Methods 621 centrally assessed HER2+ mBC patients were enrolled, 202 of whom were Asian. Those with stable, asymptomatic brain metastases (BM) were eligible for study entry. Patients were randomized 1:1 to N (240 mg qd) + C (750 mg/m 2 bid, day 1–14) with loperamide prophylaxis or to L (1250 mg qd) + C (1000 mg/m 2 bid, day 1–14) in 21-day cycles. Co-primary endpoints were centrally assessed progression-free survival (PFS) and overall survival (OS). Secondary endpoints included time to intervention for central nervous system (CNS) disease, objective response rate, duration of response (DoR), clinical benefit rate, and safety. Results 104 and 98 Asian patients were randomly assigned to receive N+C or L+C, respectively. Median PFS of N+C and L+C was 7.0 and 5.4 months ( P  = 0.0011), respectively. Overall cumulative incidence of intervention for CNS disease was lower with N+C (27.9 versus 33.8%; P  = 0.039). Both median OS (23.8 versus 18.7 months; P  = 0.185) and DoR (11.1 versus 4.2 months; P  < 0.0001) were extended with N+C, compared to L+C. The incidences of grade 3/4 treatment emergent adverse events (TEAEs) and TEAEs leading to treatment discontinuation were mostly comparable between the two arms. Diarrhea and palmar-plantar erythrodysesthesia were the most frequent TEAEs in both arms, similar to the overall population in incidence and severity. Conclusion Consistent with the efficacy profile observed in the overall study population, Asian patients with HER2+ mBC, who had received ≥ 2 HER2-directed regimens, may also benefit from N+C. No new safety signals were noted. Clinical trial registration NCT01808573